WEBSITE BSE:544409 NSE: ASTONEALAB Inc. Year: 2017 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock
Last updated: 11:03
No Notes Added Yet
Astonea Labs Ltd is an Indian company engaged in the research, development, and manufacturing of pharmaceutical and healthcare products. It focuses on producing medicines, supplements, and related healthcare solutions for domestic and international markets. The company emphasizes quality control, compliance with regulatory standards, and innovation in its product offerings. Through its operations, Astonea Labs aims to cater to healthcare needs while expanding its presence in the pharmaceutical sector
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹171 Cr.
Stock P/E 32
P/B 3.1
Current Price ₹163
Book Value ₹ 53.4
Face Value 10
52W High ₹185
Dividend Yield 0%
52W Low ₹ 0
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|
| Net Sales | 30 | 67 | 80 | 98 | |
| Other Income | 0 | 0 | 0 | 0 | |
| Total Income | 30 | 67 | 80 | 98 | |
| Total Expenditure | 24 | 60 | 68 | 82 | |
| Operating Profit | 6 | 7 | 12 | 15 | |
| Interest | 2 | 2 | 3 | 4 | |
| Depreciation | 4 | 4 | 4 | 5 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | |
| Profit Before Tax | 1 | 1 | 5 | 7 | |
| Provision for Tax | 0 | 0 | 1 | 2 | |
| Profit After Tax | 0 | 1 | 4 | 5 | |
| Adjustments | 0 | 0 | 0 | 0 | |
| Profit After Adjustments | 0 | 1 | 4 | 5 | |
| Adjusted Earnings Per Share | 0.3 | 0.9 | 5.4 | 6.9 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 23% | 48% | 0% | 0% |
| Operating Profit CAGR | 25% | 36% | 0% | 0% |
| PAT CAGR | 25% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 35% | 28% | 22% | 22% |
| ROCE Average | 17% | 14% | 12% | 12% |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Shareholder's Funds | 7 | 8 | 12 | 18 |
| Minority's Interest | 0 | 0 | 0 | 0 |
| Borrowings | 22 | 19 | 20 | 22 |
| Other Non-Current Liabilities | 1 | 1 | 1 | 0 |
| Total Current Liabilities | 23 | 36 | 49 | 63 |
| Total Liabilities | 53 | 64 | 81 | 104 |
| Fixed Assets | 21 | 21 | 22 | 25 |
| Other Non-Current Assets | 1 | 1 | 4 | 8 |
| Total Current Assets | 31 | 43 | 55 | 71 |
| Total Assets | 53 | 64 | 81 | 104 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 1 | 0 |
| Cash Flow from Operating Activities | -5 | -1 | 8 | 9 |
| Cash Flow from Investing Activities | -3 | -3 | -8 | -11 |
| Cash Flow from Financing Activities | 8 | 4 | -0 | 2 |
| Net Cash Inflow / Outflow | -0 | 0 | -1 | -0 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 0 |
| # | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.33 | 0.88 | 5.36 | 6.93 |
| CEPS(Rs) | 5.31 | 6.05 | 10.18 | 12.86 |
| DPS(Rs) | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 9.86 | 10.73 | 15.6 | 23.85 |
| Core EBITDA Margin(%) | 19.38 | 10.65 | 14.86 | 15.69 |
| EBIT Margin(%) | 7.17 | 5.1 | 10.41 | 11.18 |
| Pre Tax Margin(%) | 1.93 | 1.61 | 6.71 | 7.25 |
| PAT Margin (%) | 0.83 | 0.99 | 5.08 | 5.49 |
| Cash Profit Margin (%) | 13.43 | 6.85 | 9.65 | 10.18 |
| ROA(%) | 0.47 | 1.14 | 5.59 | 5.78 |
| ROE(%) | 3.32 | 8.5 | 40.68 | 35.36 |
| ROCE(%) | 5.82 | 8.42 | 16.96 | 17.31 |
| Receivable days | 234.5 | 104.48 | 101.3 | 118.45 |
| Inventory Days | 86.5 | 64.7 | 94.43 | 101.42 |
| Payable days | 272.97 | 116.03 | 131.32 | 134.8 |
| PER(x) | 0 | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 1.11 | 0.6 | 0.62 | 0.63 |
| EV/Core EBITDA(x) | 5.64 | 5.44 | 4.13 | 3.94 |
| Net Sales Growth(%) | 0 | 123.08 | 19.6 | 21.61 |
| EBIT Growth(%) | 0 | 58.54 | 144.28 | 30.67 |
| PAT Growth(%) | 0 | 167.36 | 511.86 | 31.46 |
| EPS Growth(%) | 0 | 167.35 | 511.84 | 29.4 |
| Debt/Equity(x) | 3.94 | 4.41 | 3.58 | 2.9 |
| Current Ratio(x) | 1.36 | 1.17 | 1.13 | 1.12 |
| Quick Ratio(x) | 1.04 | 0.71 | 0.63 | 0.66 |
| Interest Cover(x) | 1.37 | 1.46 | 2.81 | 2.84 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 |
| # | Sep 2025 | Mar 2026 |
|---|---|---|
| Promoter | 72.3 | 72.3 |
| FII | 2.51 | 0 |
| DII | 0.35 | 0.07 |
| Public | 24.83 | 27.63 |
| Others | 0 | 0 |
| Total | 100 | 100 |
| # | Sep 2025 | Mar 2026 |
|---|---|---|
| Promoter | 0.76 | 0.76 |
| FII | 0.03 | 0 |
| DII | 0 | 0 |
| Public | 0.26 | 0.29 |
| Others | 0 | 0 |
| Total | 1.05 | 1.05 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
